Co-administration of gamma-vinyl GABA and cocaine: Preclinical assessment of safety

Patricia E. Molina, Nasim Ahmed, Mohamed Ajmal, Stephen Dewey, Nora Volkow, Joanna Fowler, Naji Abumrad

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Gamma-vinyl GABA (GVG, Vigabatrin), an irreversible inhibitor of GABA transaminase (GABA-T) that inhibits cocaine-induced place preference and self administration has been proposed as a treatment for cocaine addiction. It was therefore important to assess if there was an enhanced toxicity from the combination of GVG with cocaine. No mortality was observed with administration of GVG (60 mg/kg IV) alone (n=8) or in combination (n=6) with cocaine (5 mg/kg IV). Cocaine-induced EKG alterations were not affected by GVG pretreatment. Plasma alanine amino transferase activity was reduced by GVG treatment and this was not further modified by cocaine administration. These results suggest that acute co-administration of GVG and cocaine does not result in immediate cardiovascular or hepatic toxicity of sufficient significance, to preclude further clinical trials.

Original languageEnglish
Pages (from-to)1175-1182
Number of pages8
JournalLife Sciences
Issue number11
StatePublished - 6 Aug 1999


  • ALT
  • Addiction
  • Cardiac rhythm
  • Cocaine
  • GVG
  • MABP
  • Toxicity


Dive into the research topics of 'Co-administration of gamma-vinyl GABA and cocaine: Preclinical assessment of safety'. Together they form a unique fingerprint.

Cite this